Generative AI has become a buzzword since OpenAI introduced ChatGPT in November 2022. Its rapid emergence has not only garnered attention but also prompted serious consideration of its implications in pharmacovigilance. In a recent panel discussion at the
Indegene Digital Summit, industry experts delved into the state of adoption of Generative AI in pharmacovigilance (PV) and explored the emerging trends and challenges. The panel featured distinguished experts, including
Anand Ramanathan,
Clapton Dias and
Dr. Fatima Bhayat.
